Fig 5.

Potency of AnAPN1 as demonstrated by the median 50% effective dose (ED₅₀) and lymphoproliferative responses. (a) Proc Probit (SAS 9.2) modeling of the dose-response curve using sera collected on day 28 (4 weeks after prime vaccination of BALB/c mice) indicates an ED₅₀ in the presence of adjuvant of 21.25 μg (95% fiducial limits of 16.37 μg and 28.28 μg). (b) Immunization with unformulated and formulated AnAPN1 induces cellular proliferation in spleen cells of BALB/c mice. Splenic lymphocytes harvested from BALB/c mice 42 days after primary immunization and (14 days after boost) with various doses of AnAPN1 formulated with Alhydrogel (groups 1 to 3 [G1 to G3]). Lymphoproliferation is expressed as the stimulation index (SI) with levels of bromodeoxyuridine (BrdU) in cells cultured with concanavalin A (Con A) or AnAPN1 (17.5 and 35 μg/ml) over the levels in cells in control wells (no antigen) after 5 days.